BioXcel Therapeutics 주식 (NASDAQ: BTAI)

에 대한 최신 뉴스 BioXcel Therapeutics (NASDAQ:BTAI) 주식

BioXcel Therapeutics

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics Inc

Trading Ideas

BTAI

BioXcel Therapeutics Shares Resumed Trade

BioXcel Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 67.6%

BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale in a registered direct offering of 4,000,000 shares (the "Shares") of common stock, par value $0.001 per share ("Common Stock") (or common stock equivalents in lieu thereof), and accompanying warrants (the "Accompanying Warrants") to purchase up to 4,000,000 shares of Common Stock at a combined offering price of $3.50 per Share (or per common stock equivalent in lieu thereof) and Accompanying Warrant, for aggregate gross proceeds to the Company of approximately $14 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company (excluding the proceeds, if any, from the exercise of the Accompanying Warrants). The Accompanying Warrants have an exercise price of $4.20 per share of Common Stock, are exercisable at any time after the date of issuance, subject to certain ownership limitations, and expire five years from the date of issuance. The Company has also granted the purchasers the option, exercisable at any time and from time to time, for two weeks after the closing of this offering to purchase up to an additional 4,000,000 Shares (or common stock equivalents in lieu thereof) and Accompanying Warrants to purchase an additional 4,000,000 shares of Common Stock from the Company, at a combined offering price of $3.50 per Share (or per common stock equivalent in leu thereof) and Accompanying Warrant.
Rodman &amp; Renshaw LLC is acting as the exclusive placement agent for the offering.
The offering is expected to close on March 4, 2025, subject to customary closing conditions. The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes.

News

Offerings

BioXcel Therapeutics Announces $14M Registered Direct Offering of 4M Shares Of Common Stock And Accompanying Warrants At A Combined Price Of $3.50

BioXcel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) shares are trading higher Monday following news that the U.S. Food and Drug Administration has concluded its inspection of a site involved in the <a href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-fda-closed-its-inspection-site">company's Phase 3</a> TRANQUILITY II trial.
What To Know: The trial evaluates BXCL501 for the acute treatment of agitation associated with Alzheimer's dementia. The FDA released an Establishment Inspection Report and designated the site with a &#8220;Voluntary Action Indicated&#8221; status under 21 C.F.R.20.64(d)(3), signaling that while some minor issues may have been noted, they do not require regulatory action.
The company has also received FDA feedback on the protocol for its TRANQUILITY In-Care Phase 3 trial, which is set to evaluate BXCL501 for agitation in Alzheimer's patients residing in care facilities. The TRANQUILITY In-Care trial will assess the efficacy and safety of a 60 mcg dose of BXCL501 over 12 weeks in patients with mild to severe Alzheimer's-related dementia.
BTAI Price Action: BioXcel shares were up 117.1% at $4.68 at the time of writing, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="521" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03131335/Screenshot-2025-03-03-at-13.13.09-1024x521.png" alt="" class="wp-image-806623" style="width:414px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03131335/Screenshot-2025-03-03-at-13.13.09-1024x521.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03131335/Screenshot-2025-03-03-at-13.13.09-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03131335/Screenshot-2025-03-03-at-13.13.09-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03131335/Screenshot-2025-03-03-at-13.13.09.png 1523w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44084997/tesla-rebounds-while-tariffs-weigh-on-manufacturing-whats-driving-markets-monday">Tesla Rebounds While Tariffs Weigh On Manufacturing: What&#8217;s Driving Markets Monday?</a></li>
</ul>
Image Via Shutterstock.

Movers

BioXcel Shares Are Up Today: What's Going On?

WIIM

BioXcel Therapeutics shares are trading higher after the FDA closed its inspection of a site for the Phase 3 TRANQUILITY II trial for the acute treatment of agitation associated with Alzheimer's dementia.

BioXcel Therapeutics Shares Resume Trade Following Circuit Breaker Halt

<ul>
<li>FDA concludes site inspection is closed under 21 C.F.R.20.64(d)(3); Voluntary Action Indicated</li>
<li>Company believes this further supports reliability of data from TRANQUILITY II trial of BXCL501</li>
</ul>

Biotech

Health Care

General

BioXcel Therapeutics Announced That The FDA Concluded That The Inspection Of A Single Site In Its TRANQUILITY II Phase 3 Trial And Released The Establishment Inspection Report. The FDA Has Designated "Voluntary Action Indicated" For The Site

BioXcel Therapeutics shares are trading higher after the company announced it regained Nasdaq listing compliance.

BioXcel Therapeutics Regains Nasdaq Listing Compliance, Overcomes Bid Price Challenge

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

BioXcel Therapeutics shares are trading lower after the company announced a 1-for-16 reverse stock split.

Stock Split

BioXcel Therapeutics Announced That It Will Effect A 1-for-16 Reverse Stock Split At 5:00 P.M. Eastern Time On February 7

The majority of trial sites have been opened and patient enrollment is progressing with the SERENITY At-Home trial&nbsp;of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia.
Developed plans for the&nbsp;TRANQUILITY In-Care trial&nbsp;of BXCL501 for agitation associated with Alzheimer's dementia (AAD).

BioXcel Therapeutics Updates On Progress Of Its Late-stage Clinical Programs For Lead Neuroscience Asset BXCL501

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) with a Buy and lowers the price target from $5 to $3.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $3

Shares of Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) rose sharply in today's pre-market trading after the company provided <a href="https://www.benzinga.com/news/earnings/25/01/43179578/twilio-stock-is-trading-higher-after-hours-whats-going-on">preliminary financial results for the fourth quarter.</a>
After the market close on Thursday, Twilio introduced new financial expectations in a regulatory filing. The company said it now expects fourth-quarter revenue growth of approximately 11% year-over-year, up from prior guidance of 7% to 8%.
Twilio shares jumped 18.5% to $134.40 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Allurion Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) gained 87.6% to $6.94 in pre-market trading after the company announced its intention to initiate a clinical study combining its Allurion program with GLP-1 agonists to improve muscle mass and overall body composition.</li>
<li>Starbox Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) gained 76.4% to $0.8999 in pre-market trading after dropping around 18% on Thursday. Starbox Group recently announced the launch of its StarboxAI-IntelliContentCreate platform.</li>
<li>Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) rose 55% to $5.64 in pre-market trading after jumping 53% on Thursday. Evaxion recently said it completed dosing in phase 2 trial with personalized cancer vaccine EVX-01.</li>
<li>Dogwood Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) gained 44.6% to $19.30 in pre-market trading after jumping 377% on Thursday. Dogwood Therapeutics recently announced patient dosing for its Phase 2b trial evaluating halneuron will commence in the first quarter.</li>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) rose 27.1% to $0.0549 in pre-market trading. Aclarion recently announced the pricing of $14.4m public offering of common stock and warrants.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) gained 25.5% to $1.87 in pre-market trading after the company announced it regained Nasdaq compliance regarding the minimum bid pricing list requirement.</li>
<li>BioXcel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) gained 21.5% to $0.4616 in pre-market trading after gaining over 4% on Thursday.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) gained 17.5% to $0.57 in pre-market trading after the company launched the LaunchBox monitor in Canada.</li>
<li>Septerna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) rose 14.2% to $20.99 in pre-market trading following a 5% decline on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Hyzon Motors Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYZN#NASDAQ">HYZN</a>) fell 46% to $0.4172 in pre-market trading. Hyzon Motors, last month, issued a worker adjustment and retraining notification and cited the inability to raise funding and uncertainty related to the availability of government subsidies.</li>
<li>Centessa Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) shares fell 38.5% to $10.01 in pre-market trading.</li>
<li>Mineralys Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) fell 29.8% to $7.20 in pre-market trading.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares tumbled 28.1% to $0.9999 in pre-market trading after jumping more than 5% on Thursday.</li>
<li>DallasNews Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) shares fell 18.4% to $5.61 in pre-market trading after gaining over 3% on Thursday.</li>
<li>First Financial Bancorp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFBC#NASDAQ">FFBC</a>) dipped 13.8% to $24.11 in pre-market trading after the company reported fourth-quarter results.</li>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) fell 13.4% to $0.0433 in pre-market trading. Conduit Pharmaceuticals shares dipped 20% on Thursday after the company board approved a 1-for-100 reverse stock split.</li>
<li>Valens Semiconductor Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>) declined 12% to $2.58 in pre-market trading after declining 3% on Thursday.</li>
<li>Acacia Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) fell 11.7% to $3.86 in today's pre-market trading.</li>
<li>PB Bankshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBBK#NASDAQ">PBBK</a>) shares dipped 10% to $13.59 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>

Pre-Market Outlook

Markets

ACON

ACTG

ALUR

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket

BioXcel Therapeutics Files For Resale Of Up To 5.1M Shares By The Selling Stockholders

BioXcel Therapeutics shares are trading lower after B of A Securities downgraded the stock from Buy to Underperform and cut its price target from $7 to $0.25.

B of A Securities analyst Geoff Meacham downgrades BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) from Buy to Underperform and lowers the price target from $7 to $0.25.

Downgrades

B of A Securities Downgrades BioXcel Therapeutics to Underperform, Lowers Price Target to $0.25

BioXcel Therapeutics shares are trading higher. Canaccord Genuity maintained a Buy rating on the stock.

Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) with a Buy and lowers the price target from $7 to $5.

Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5

Press Releases

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia

Earnings

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

IPOs

BioXcel Therapeutics Announces Proposed Public Offering

Financing

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Management

BioXcel Therapeutics Provides Clinical and Business Update

BioXcel Therapeutics Announces Reverse Stock Split

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AIM ImmunoTech

Aprea Therapeutics

BioCardia

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Imunon

Immuron Limited - American Depositary Shares

Immuron

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

MetaVia

Mainz Biomed

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Ocean Biomedical

Organovo Holdings

BiomX

PharmaCyte Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Comments

BioXcel Therapeutics

뉴스

에 대한 최신 뉴스 BioXcel Therapeutics (NASDAQ:BTAI) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌